7SS Stock Chart & Stats
€0.19
<€0.01(7.63%)
At close: 4:00 PM EST
€0.19
<€0.01(7.63%)
Day’s Range― - ―
52-Week Range€0.09 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)42.00
Market Cap
€71.03M
Enterprise Value-€1.40K
Total Cash (Recent Filing)€1.77B
Total Debt (Recent Filing)€6.18M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding734,958,250
10 Day Avg. Volume0
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityVery low leverage reduces financial risk and preserves flexibility to fund operations, pursue development opportunities, or absorb setbacks. Positive equity through 2025 provides a capital cushion, although historical losses show this strength has not eliminated financial pressures.
Improved 2025 Losses And Cash BurnThe reduction in cash burn and losses during 2025 indicates some progress in financial discipline and operating performance. If sustained, this improvement could extend liquidity and reduce funding pressure, even though cash generation remains negative and the business is not yet self-sustaining.
Partnered Product And Commercialization ModelA partnered model can provide access to externally originated therapies, shared development costs, and milestone or royalty opportunities without requiring Brii to fund every program independently. This structure supports asset access and commercialization reach across infectious-disease markets.
Bears Say
Persistent Operating And Free Cash BurnContinued negative operating and free cash flow means the business does not currently fund its activities internally. Persistent cash burn can consume liquidity and leave future development dependent on existing resources or external funding, limiting strategic flexibility if losses continue.
Sustained Losses And Negative MarginsOngoing losses and deeply negative margins show that the business has not yet reached sustainable profitability. Without durable margin improvement, future revenue growth may not translate into stronger cash generation, while accumulated losses can continue to constrain long-term financial resilience.
Sharp Recent Revenue ContractionA sharp revenue decline after volatile performance signals weak scale and an uncertain commercial trajectory. Lower revenue can reduce operating leverage and make it harder to absorb research, development, and commercialization costs, reinforcing the challenge of reaching sustainable profitability.
Brii Biosciences Limited News
7SS FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was €0.09 and its highest was €0.26 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is €71.03M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 184 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.014 by -€0.004.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,958,250 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.014. Following the earnings report the stock price went up 5.155%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in DE:7SS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Technical Analysis
Mabpharm Limited
―
Clover Biopharmaceuticals Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Transcenta Holding Limited
―
AIM Vaccine Co., Ltd. Class H
―